FOLH1 and prostate carcinoma: In localized HR / BCR prostate cancer patients there are relatively few CTCs therefore, one of the exploratory objectives of this clinical trial was to investigate whether CTC count can be used as a clinical marker in lieu of repeated PSMA PET scans.